InvestorsHub Logo
Followers 137
Posts 22855
Boards Moderated 0
Alias Born 04/08/2004

Re: La Flaca post# 328474

Tuesday, 08/31/2021 6:29:15 PM

Tuesday, August 31, 2021 6:29:15 PM

Post# of 458325
Projection!!!

Pfizer cash on hand for the quarter ending June 30, 2021 was $21.700B, a 4.8% decline year-over-year.

That amount of cash along with an equal amount of PFE stock should make a pretty good up front payment for say 40% of Anavex Life Sciences.




In a couple of years Anavex will have sales of Blarcamesine.

It is estimated that there are approximately 44 million people worldwide living with Alzheimer's disease or a related form of dementia. In the U.S., an estimated 5.5 million people of all ages have Alzheimer's disease.


If we estimate that in couple of years 10% of Alzheimer’s patients start taking Blarcamesine each and every day at a price of say $10.00 per day, then 4,400,000 patients at $10.00 per day would be sales starting at 308 million per week. That would be $16 billion per year. With a conservative profit margin of just 50% that would be $8 billion in profit/earnings. $8,000,000,000 divided by an estimate of 100,000,000 shares would be a profit/earnings of $80.00 per share. With a conservative PE ratio of just 20, then that would equate to conservatively $1600 per share for AVXL.


Good luck and GOD bless,
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News